Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Inhale Therapeutic Syst. (NasdaqNM:INHL)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Recent Events
Aug 22Price hit new 52-week low ($13.75)
Aug  8Earnings Announcement
Location
150 Industrial Road
San Carlos, CA 94070
Phone: (650) 631-3100
Fax: (650) 354-0701
Email: joycestrand@inhale.com
Employees (last reported count): 485
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Medical Equipment & Supplies
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 47%
·Institutional: 77% (145% of float)
(305 institutions)
·Net Inst. Buying: 3.51M shares (+7.69%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Inhale Therapeutic Systems, Inc. is a supplier of drug delivery solutions. The Company is creating a drug delivery system to deliver a wide range of drugs, including peptides, proteins, nucleic acids and other molecules, by inhalation to the deep lung. Inhale Therapeutic Systems is using this system principally to enable non-invasive delivery of macromolecule drugs otherwise administered by injection. The Company's most advanced program, which is sponsored by Pfizer Inc., is inhalable insulin. In addition to its insulin program with Pfizer, the Company has development collaborations with Biogen, Inc., Aventis Behring L.L.C. (formerly Centeon L.L.C., a joint venture of Hoechst AG and Rhone-Poulenc S.A., which have now merged to form Aventis S.A.) and Eli Lilly & Co. The Company also has early stage feasibility and research collaborations with several other companies, and has tested eight drugs in clinical trials.
More from Market Guide: Expanded Business Description

Financial Summary
Inhale Therapeutic Systems is creating an inhalation drug delivery system to deliver peptides, proteins and other macromolecule drugs into the deep lung. For the six months ended 6/30/01, revenues increased 27% to $30.9 million. Net loss totaled $186.8 million, up from $44.6 million. Revenues reflect the expansion of the Company's collaborative agreement with Pfizer, Inc. Higher loss reflects a $83.6 million charge for in-process research and development.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Robert Chess, 44
Chairman
$926K$7.3M
Ajit Gill, 52
Pres, CEO, Director
1.1M7.9M
Brigid Makes, 45
CFO, Assistant Sec., VP of Fin. and Admin.
283K--  
John Patton, Ph.D., 54
VP, Research
303K--  
Stephen Hurst, 45
Sec., Gen. Counsel, VP
271K3.4M
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:INHLAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Aug-2001
$13.75 
Recent Price$14.53 
52-Week High
on 2-Oct-2000
$60.25 
Beta1.11 
Daily Volume (3-month avg)1.41M
Daily Volume (10-day avg)396.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-71.0%
52-Week Change
relative to S&P500
-61.1%
Share-Related Items
Market Capitalization$797.1M
Shares Outstanding54.9M
Float29.1M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 23-Aug-2000
Per-Share Data
Book Value (mrq)$5.99 
Earnings (ttm)-$4.82 
Earnings (mrq)-$2.05 
Sales (ttm)$1.22 
Cash (mrq)$7.03 
Valuation Ratios
Price/Book (mrq)2.42 
Price/EarningsN/A 
Price/Sales (ttm)11.92 
Income Statements
Sales (ttm)$58.1M
EBITDA (ttm)-$221.9M
Income available to common (ttm)-$239.7M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-41.41%
Return on Equity (ttm)-96.58%
Financial Strength
Current Ratio (mrq)6.84 
Debt/Equity (mrq)0.99 
Total Cash (mrq)$385.7M
Short Interest
As of 8-Aug-2001
Shares Short4.15M
Percent of Float14.3%
Shares Short
(Prior Month)
5.80M
Short Ratio2.61 
Daily Volume1.59M
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.